Go Pro
NASDAQ:ONC

BeOne Medicines Q1 2026 Earnings Report

BeOne Medicines logo
$356.01 -3.04 (-0.85%)
Closing price 08/13/2026 04:00 PM Eastern
Extended Trading
$351.88 -4.13 (-1.16%)
As of 07:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines EPS Results

Actual EPS
$0.25
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

BeOne Medicines Revenue Results

Actual Revenue
$1.51 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BeOne Medicines Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

BeOne Medicines Earnings Headlines

They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
UBS Keeps Their Buy Rating on BeOne Medicines Ltd (6160)
See More BeOne Medicines Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BeOne Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeOne Medicines and other key companies, straight to your email.

About BeOne Medicines

BeOne Medicines (NASDAQ:ONC) Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

View BeOne Medicines Profile